

Remarks

Claims 61-63 and 67-94 are pending in this application. Claims 64-66 are canceled without prejudice to Applicants' right to pursue the subject matter recited by them in one or more divisional, continuation, and continuation-in-part applications. Claims 83-94 are added in this paper. Claims 83-94 are fully supported by the specification and claims as originally filed. For example, pharmaceutically acceptable salts of venlafaxine derivatives are listed on page 5, lines 18-25 of the specification. Supports for other limitations of claims 83-94 are substantially identical to those provided for claims 61-82 in Applicants' preliminary amendment filed March 23, 2004. No new matter has been introduced.

A fee of \$ 1,700.00 is believed due for the additional claims. If any other fees are required for the submission of this paper, or to avoid abandonment of this application, please charge such fees to Jones Day Deposit Account No. 503013.

Date March 29, 2005

Respectfully submitted,


Max Bachrach

45,479

Reg. No.

Jones Day
51 Louisiana Avenue, N.W.
Washington, DC 20001-2113
(202) 879-3939

For: Thomas E. Friebe (Reg. No. 29,258)
Jones Day
222 East 41st Street
New York, New York 10017
(212) 326-3939